Beta-Blockers Best Avoided in COPD Patients Without CVD
Trial appears to settle an outstanding clinical question
Related Articles
New COVID Variant XEC May Outpace Others This Fall
No signs of meaningfully different symptoms or vaccine response, experts say
Aly-Khan A. Lalani, MD, on Use of Systemic Therapies for Metastatic RCC in Canada
Over the last 20 years, standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have progressed from cytokines and vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs)…
Opinion | Brain Health Risks: Digital Quality Measures and the Future of Neurological Care
Access to advanced tools must be equitable
Opinion | Direct-to-Consumer Drugs: Big Pharma’s Digital Health Play
Regulators will need to closely watch this new frontier
How to Get Started as a Nurse Advocate Around Key Issues Like Scope of Practice AJN Off the Charts
This overview was developed as an introduction to the process of impacting legislative change as an advocate for your patients and your profession. Some current…
Lp(a) Cutoffs by Sex; LBBA Pacing Approvals; Loneliness Not to Blame for CVD?
Recent developments of interest in cardiovascular medicine
‘Medical Breakthrough’ for Pneumococcal Pneumonia
The first-in-human of the novel antitoxin liposomal agent CAL02 demonstrated
Mpox Is Back in the News. Here’s What Clinicians Need to Know.
This new surge is different, WHO leader says
CDC: U.S. Falls Short in Improving QoL for Older People With HIV
Addressing shortcomings will require moving ‘beyond clinical care,’ agency says
Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes
Type 2 diabetes is a risk factor for development of cirrhosis and hepatocellular carcinoma. However, risk factors that identify persons with the highest risk for…